Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
Public ClinicalTrials.gov record NCT03691974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee. The secondary objectives of the study are to: * Evaluate the efficacy of fasinumab compared to placebo in participants with pain due to OA of the hip or knee * Evaluate the safety and tolerability of fasinumab compared to placebo in participants with pain due to OA of the hip or knee * Characterize the concentrations of fasinumab in serum in participants with pain due to OA of the hip or knee * Evaluate the immunogenicity of fasinumab in participants with pain due to OA of the hip or knee.
Study identification
- NCT ID
- NCT03691974
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2018 (Actual)
- Primary completion
- Jan 30, 2020 (Actual)
- Completion
- Jan 7, 2021 (Actual)
- Last update posted
- Mar 1, 2023
2018 – 2021
United States locations
- U.S. sites
- 21
- U.S. states
- 9
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Glendale | Arizona | 85306 | — |
| Regeneron Study Site | Glendale | Arizona | 85308 | — |
| Regeneron Study Site | Phoenix | Arizona | 85053 | — |
| Regeneron Study Site | Tucson | Arizona | 85412 | — |
| Regeneron Study Site | Anaheim | California | 92805 | — |
| Regeneron Study Site | Clearwater | Florida | 33756 | — |
| Regeneron Study Site | Jacksonville | Florida | 32256 | — |
| Regeneron Study Site | Miami | Florida | 33165 | — |
| Regeneron Study Site | Ocoee | Florida | 34761 | — |
| Regeneron Study Site | Orlando | Florida | 32808 | — |
| Regeneron Study Site | Woodstock | Georgia | 30189 | — |
| Regeneron Study Site | Chicago | Illinois | 60607 | — |
| Regeneron Study Site | Chicago | Illinois | 60611 | — |
| Regeneron Study Site | Caro | Michigan | 48723 | — |
| Regeneron Study Site | Hartsdale | New York | 10530 | — |
| Regeneron Study Site | Cincinnati | Ohio | 45224 | — |
| Regeneron Study Site | Columbus | Ohio | 43235 | — |
| Regeneron Study Site | Bellaire | Texas | 77401 | — |
| Regeneron Study Site | Houston | Texas | 77004 | — |
| Regeneron Study Site | Houston | Texas | 77058 | — |
| Regeneron Study Site | San Antonio | Texas | 72858 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03691974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03691974 live on ClinicalTrials.gov.